| Literature DB >> 33688718 |
Pamela Brown1,2, Omar Abdulle1, Steven Boakes1, Naomi Divall1, Esther Duperchy1, Sonia Ganeshwaran1, Roy Lester1, Stephen Moss3, Dean Rivers1, Mona Simonovic1, Jaspal Singh1, Steven Stanway3, Antoinette Wilson3, Michael J Dawson1,2.
Abstract
Novel polymyxin derivatives are often classified either as having direct activity against Gram-negative pathogens or as compounds inactive in their own right, which through permeabilization of the outer membrane act as potentiators of other antibiotics. Here, we report the systematic investigation of the influence of lipophilicity on microbiological activity (including against strains with reduced susceptibility to polymyxins), potentiation of rifampicin, and in vitro toxicity within a series of next-generation polymyxin nonapeptides. We demonstrate that the lipophilicity at the N-terminus and amino acids 6 and 7 in the cyclic peptide core is interchangeable and that the activity, ability to potentiate, and cytotoxicity all appear to be primarily driven by overall lipophilicity. Our work also suggests that the characterization of a polymyxin molecule as either a direct acting compound or a potentiator is more of a continuum that is strongly influenced by lipophilicity rather than as a result of fundamentally different modes-of-action.Entities:
Keywords: Gram-negative; antimicrobial resistance; lipophilicity; multidrug-resistant bacteria; polymyxin; potentiator
Mesh:
Substances:
Year: 2021 PMID: 33688718 PMCID: PMC8138958 DOI: 10.1021/acsinfecdis.0c00917
Source DB: PubMed Journal: ACS Infect Dis ISSN: 2373-8227 Impact factor: 5.084